Sergliflozin etabonate

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1].

Research Areas >> Metabolic Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT

SGLT2

Sergliflozin etabonate (1、3、10、30 mg/kg；口服；一次) 以剂量依赖性方式显着降低 KK-Ay 小鼠的非空腹血糖水平[1]。 Sergliflozin etabonate (1.7、8.4、45.7 mg/kg饲料含有 0.001、0.005 和 0.025% sergliflozin etabonate；进食；每天服用，持续 9 周) 以剂量依赖的方式降低非空腹血糖水平并降低肝脏中的甘油三酯含量 在 KK-Ay 小鼠中[1]。 Animal Model: 14 weeks, Female KK-Ay mice[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Oral; once Result: Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. Animal Model: 4 weeks, Female KK-Ay mice[1] Dosage: 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate Administration: Fed, daily for 9 weeks Result: Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice.

[1]. Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104.